Morning Briefing
Summaries of health policy coverage from major news organizations
$50 Price For Over-The-Counter Narcan May Be Too High For Many Consumers
When Narcan finally becomes available over the counter later this year, the price may put the lifesaving antidote out of reach for many people, experts say. Emergent BioSolutions said Thursday that it plans to price the opioid overdose reversal medication at less than $50 for two doses. (Lovelace Jr., 4/20)
But advocates have long worried that the price of Narcan 鈥 a 4-milligram spray version of the liquid drug naloxone that comes two to a kit 鈥 might be a barrier for those who need it the most. 鈥淚t鈥檚 still too expensive for pretty much everyone I鈥檝e ever provided it to 鈥 mainly teens and people experiencing homelessness,鈥 said Chelsea Shover, a professor of epidemiology at UCLA. 鈥淭hat price point is probably fine for many businesses or organizations who want or have to have a Narcan kit or two publicly available.鈥 (Ovalle, 4/20)
More on the opioid crisis 鈥
Democratic and Republican California lawmakers in the Assembly struck a deal on Thursday to hold a special hearing on a handful of fentanyl-related bills after Republicans threatened to force a floor vote on the legislation. The effort comes after the chairman of the Assembly Public Safety Committee announced he would not hear any more fentanyl-related bills until a special hearing he hoped to have in June on the issue. (Zavala, 4/20)
杨贵妃传媒視頻 Health News: The Biden Administration Vowed To Be A Leading Voice On Opioid Settlements But Has Gone Quiet
Early in President Joe Biden鈥檚 tenure, his administration promised to play a key role in ensuring opioid settlement funds went toward tackling the nation鈥檚 addiction crisis. During the 2020 campaign, Biden had laid out a plan to appoint an 鈥渙pioid crisis accountability coordinator鈥 to support states in their lawsuits against companies accused of sparking the overdose epidemic. The following year, the White House convened a meeting about the soon-to-be finalized settlements, noted that the money could support drug policy priorities, and helped create a model law that states could adopt in anticipation of receiving funds. (Pattani, 4/21)
Drug dealers are mixing xylazine, an animal tranquilizer relied on by veterinarians, into fentanyl, with deadly results. But controlling it is tricky. (Hoffman, 4/20)